You are here

Article Text

Article menu
Download PDFPDF
Research letter
SARS-CoV-2 vaccination of people living with human T leukaemia virus type 1
  1. Abelardo Araujo1,
  2. Fabiola Martin2
  1. 1 National Institute of Infectious Diseases, Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil
  2. 2 School of Public Health, University of Queensland, Brisbane, Queensland, Australia
  1. Correspondence to Dr Fabiola Martin, School of Public Health, The University of Queensland Faculty of Medicine, Herston, QLD 4006, Australia; fabiola.az.martin{at}gmail.com

https://doi.org/10.1136/sextrans-2021-055007

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Several SARS-CoV-2 vaccines are being rolled out worldwide, following testing in healthy volunteers and smaller groups of people with comorbidities, including HIV.1 Human T-cell leukaemia virus type 1 (HTLV-1), a retrovirus like HIV, is oncogenic and can cause chronic immune dysfunction. However, there is no established antiretroviral treatment for HTLV-1. An estimated 10 million individuals live with HTLV-1 worldwide. Two main disease patterns are recognised: lymphoproliferative immunodeficient (adult T-cell leukaemia/lymphoma) and inflammatory immunodysfunctional (HTLV-1-associated myelopathy).

    HTLV-1 is an under-researched virus, only recently adopted …

    View Full Text

    Footnotes

    • Handling editor Anna Maria Geretti

    • Contributors AA conceived the idea of this project and coauthored the manuscript. FM reviewed and coauthored the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.